Our company continues to increase investment in R&D, focusing on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (“CNS”) and anti-infectives, and is committed to improving human health through continuous innovation. To date, Our company already has 7 innovative drugs generating sales revenue in China.
The only globally approved and marketed innovative small-molecule peptide-based compound for the treatment of renal anemia.
The first CD19-targeted monoclonal antibody approved in China.
The first original third-generation EGFR-TKI innovative drug in China; The first China-originated EGFR-TKI approved overseas.
The first wholly developed oral dose medicine indicated for the treatment of hepatitis B virus (HBV) infection in China.
The first original second-generation TKI for chronic myelogenous leukemia in China.
First original GLP-1RA weekly formulation in China.
The world's first nitroimidazole anti-anaerobic innovative drug over the past 40 years.
